A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus

被引:33
作者
Abed, Yacine
Baz, Mariana
Boivin, Guy [1 ]
机构
[1] CHUQ CHUL, Res Ctr Infect Dis, Ste Foy, PQ G1V 4G2, Canada
基金
加拿大健康研究院;
关键词
IMMUNOCOMPROMISED PATIENT; ANTIVIRAL THERAPY; HIGHLY POTENT; IN-VITRO; A VIRUS; INHIBITORS; INFECTIONS;
D O I
10.1086/595736
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neuraminidase (NA) mutations responsible for influenza resistance to oseltamivir vary according to the NA subtype; in influenza A/H3N2 viruses, NA-gene mutations occur predominantly at codons E119 and R292. In an oseltamivir-resistant influenza A/H3N2 virus isolated from an immunocompromised child after 107 days of cumulative treatment, the NA gene contained 3 aa substitutions (N146K, S219T, and A272V) and a 4-aa deletion (Del245-248); reversion mutation experiments using recombinantNAproteins determined that the deletion was the sole change responsible for resistance to oseltamivir. This study highlights the diversity of mechanisms of resistance to oseltamivir in clinical settings, reinforcing the need for novel anti-influenza strategies.
引用
收藏
页码:180 / 183
页数:4
相关论文
共 15 条
  • [1] Abed Y, 2006, ANTIVIR THER, V11, P971
  • [2] Treatment of respiratory virus infections
    Abed, Yacine
    Boivin, Guy
    [J]. ANTIVIRAL RESEARCH, 2006, 70 (02) : 1 - 16
  • [3] Aoki FY, 2007, ANTIVIR THER, V12, P603
  • [4] BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design
    Babu, YS
    Chand, P
    Bantia, S
    Kotian, P
    Dehghani, A
    El-Kattan, Y
    Lin, TH
    Hutchison, TL
    Elliott, AJ
    Parker, CD
    Ananth, SL
    Horn, LL
    Laver, GW
    Montgomery, JA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (19) : 3482 - 3486
  • [5] Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir
    Baz, Mariana
    Abed, Yacine
    Boivin, Guy
    [J]. ANTIVIRAL RESEARCH, 2007, 74 (02) : 159 - 162
  • [6] Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an Immunocompromised child
    Baz, Mariana
    Abed, Yacine
    McDonald, Jane
    Boivin, Guy
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (12) : 1555 - 1561
  • [7] Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an Immunocompromised patient
    Boivin, G
    Goyette, N
    Bernatchez, H
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) : E23 - E25
  • [8] SEQUENCE AND STRUCTURE ALIGNMENT OF PARAMYXOVIRUS HEMAGGLUTININ-NEURAMINIDASE WITH INFLUENZA-VIRUS NEURAMINIDASE
    COLMAN, PM
    HOYNE, PA
    LAWRENCE, MC
    [J]. JOURNAL OF VIROLOGY, 1993, 67 (06) : 2972 - 2980
  • [9] Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors
    Gubareva, LV
    [J]. VIRUS RESEARCH, 2004, 103 (1-2) : 199 - 203
  • [10] In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication
    Kati, WM
    Montgomery, D
    Carrick, R
    Gubareva, L
    Maring, C
    McDaniel, K
    Steffy, K
    Molla, A
    Hayden, F
    Kempf, D
    Kohlbrenner, W
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1014 - 1021